Mark Baum, Harrow CEO
July 19, 2023 10:51 AM EDT
Financing

Har­row prices $60M of­fer­ing one day af­ter ac­quir­ing US, Cana­di­an rights to new dry eye treat­ment

Paul Schloesser

Associate Editor

Eye biotech Har­row Health is look­ing to raise $60 mil­lion af­ter buy­ing the rights to an eye prod­uct new­ly ap­proved by the FDA.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times